Drd2m1Anu/Drd2m1Anu
C57BL/NCrlAnu-Drd2m1Anu/Anu
|
no abnormal phenotype detected |
J:104190
|
Drd2tm1.1Mmsh/Drd2tm1.1Mmsh Gng7tm1(cre)Mmsh/?
involves: C57BL/6N
|
normal
behavior/neurological phenotype |
J:210178
|
Drd2tm1.1Mrub/Drd2tm1.1Mrub Slc6a3tm1.1(cre)Bkmn/Slc6a3+
B6.Cg-Drd2tm1.1Mrub Slc6a3tm1.1(cre)Bkmn
|
abnormal inhibitory postsynaptic currents |
J:176167
|
abnormal operant conditioning behavior |
J:176167
|
abnormal single cell response |
J:176167
|
abnormal synaptic dopamine release |
J:176167
|
decreased physiological sensitivity to xenobiotic |
J:176167
|
enhanced behavioral response to cocaine |
J:176167
|
hyperactivity |
J:176167
|
increased physiological sensitivity to xenobiotic |
J:176167
|
induced hyperactivity |
J:176167
|
Drd2tm1.1Mrub/Drd2tm1.1Mrub Tg(Nes-cre)1Kln/?
involves: 129S4/SvJae * C57BL/6 * SJL
|
abnormal hormone level |
J:194227
|
abnormal social/conspecific interaction behavior |
J:194227
|
normal
behavior/neurological phenotype |
J:194227
|
decreased circulating insulin-like growth factor I level |
J:194227
|
decreased growth hormone level |
J:194227
|
decreased physiological sensitivity to xenobiotic |
J:194227
|
decreased somatotroph cell number |
J:194227
|
decreased urine major urinary protein level |
J:194227
|
normal
homeostasis/metabolism phenotype |
J:194227
|
postnatal growth retardation |
J:194227
|
slow postnatal weight gain |
J:194227
|
Drd2tm1.1Mrub/Drd2tm1.1Mrub Tg(Prl-cre)1Mrub/?
involves: 129S4/SvJae * C57BL/6 * CBA
|
decreased physiological sensitivity to xenobiotic |
J:194227
|
normal
growth/size/body region phenotype |
J:194227
|
increased circulating prolactin level |
J:194227
|
Drd2tm1Ebo/Drd2+
involves: 129S2/SvPas * C57BL/6
|
abnormal behavior |
J:96229
|
catalepsy |
J:29045
|
decreased locomotor activity |
J:29045,
J:96229
|
decreased vertical activity |
J:29045
|
Drd2tm1Ebo/Drd2tm1Ebo
B6.129S2-Drd2tm1Ebo
|
increased susceptibility to neuronal excitotoxicity |
J:65767
|
Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
|
abnormal adrenal gland zona fasciculata morphology |
J:110599
|
abnormal adrenal gland zona reticularis morphology |
J:110599
|
abnormal behavior |
J:96229
|
abnormal estrous cycle |
J:41857
|
abnormal estrus |
J:41857
|
abnormal gait |
J:29045
|
abnormal melanotroph morphology |
J:110599
|
abnormal neuron physiology |
J:65767
|
abnormal pituitary gland physiology |
J:110599
|
adenohypophysis hyperplasia |
J:41857
|
adrenal cortical hyperplasia |
J:110599
|
akinesia |
J:29045
|
normal
behavior/neurological phenotype |
J:111282
|
bradykinesia |
J:29045
|
catalepsy |
J:29045
|
decreased body temperature |
J:29045
|
decreased body weight |
J:29045
|
decreased circulating estrogen level |
J:41857
|
decreased circulating growth hormone level |
J:41857
|
decreased fluid intake |
J:29045
|
decreased food intake |
J:29045
|
decreased lactotroph cell size |
J:41857
|
decreased locomotor activity |
J:29045,
J:96229
|
decreased somatotroph cell number |
J:41857
|
decreased vertical activity |
J:29045,
J:96229
|
enlarged adrenocortical cells |
J:110599
|
enlarged pituitary gland |
J:41857
|
hyperpigmentation |
J:110599
|
hypersecretion of corticosterone |
J:110599
|
impaired conditioned place preference behavior |
J:111282
|
impaired coordination |
J:29045
|
increased circulating adrenocorticotropin level |
J:110599
|
increased circulating corticosterone level |
J:110599
|
increased circulating pituitary hormone level |
J:110599
|
increased circulating prolactin level |
J:41857
|
increased lactotroph cell number |
J:41857
|
increased pituitary adenoma incidence |
J:41857
|
increased susceptibility to neuronal excitotoxicity |
J:65767
|
increased susceptibility to pharmacologically induced seizures |
J:65767
|
increased thyrotroph cell number |
J:41857
|
limp posture |
J:29045
|
pituitary gland hyperplasia |
J:41857
|
pituitary intermediate lobe hyperplasia |
J:41857,
J:110599
|
prolonged diestrus |
J:41857
|
reduced female fertility |
J:41857
|
reduced fertility |
J:29045
|
small ovary |
J:29045
|
small testis |
J:29045
|
Drd2tm1Low/Drd2+
129S/Sv-Drd2tm1Low
|
abnormal locomotor behavior |
J:47001
|
Drd2tm1Low/Drd2+
B6.129S2-Drd2tm1Low
|
abnormal locomotor behavior |
J:47001
|
abnormal systemic arterial blood pressure |
J:103181
|
ataxia |
J:50787
|
normal
behavior/neurological phenotype |
J:50787
|
decreased locomotor activity |
J:50787
|
decreased vertical activity |
J:47001
|
impaired behavioral response to alcohol |
J:50787
|
increased body weight |
J:103181
|
increased mean systemic arterial blood pressure |
J:103181
|
increased systemic arterial diastolic blood pressure |
J:103181
|
increased systemic arterial systolic blood pressure |
J:103181
|
Drd2tm1Low/Drd2+
involves: 129S2/SvPas * C57BL/6J
|
abnormal locomotor behavior |
J:47001
|
increased physiological sensitivity to xenobiotic |
J:47001
|
Drd2tm1Low/Drd2tm1Low
129S/Sv-Drd2tm1Low
|
abnormal locomotor activation |
J:47001
|
abnormal locomotor behavior |
J:47001
|
Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2tm1Low
|
abnormal brain development |
J:127071
|
abnormal CNS synaptic transmission |
J:127071
|
abnormal excitatory postsynaptic currents |
J:127071
|
abnormal latent inhibition of conditioning behavior |
J:90593
|
abnormal locomotor activation |
J:47001,
J:103181
|
abnormal locomotor behavior |
J:47001,
J:50787
|
abnormal operant conditioning behavior |
J:90593
|
abnormal prepulse inhibition |
J:55027
|
abnormal response to novel odor |
J:110704
|
abnormal systemic arterial blood pressure |
J:103181
|
absent long-term depression |
J:127071
|
alcohol aversion |
J:50787
|
ataxia |
J:50787
|
normal
behavior/neurological phenotype |
J:50787,
J:103181,
J:110704
|
decreased alcohol consumption |
J:50787
|
decreased body weight |
J:130701
|
decreased locomotor activity |
J:50787
|
decreased pulmonary ventilation |
J:130701
|
decreased startle reflex |
J:154428
|
decreased vertical activity |
J:47001
|
impaired behavioral response to addictive substance |
J:55027
|
impaired behavioral response to alcohol |
J:50787
|
impaired coordination |
J:47001
|
increased heart rate |
J:103181
|
increased mean systemic arterial blood pressure |
J:103181
|
increased physiological sensitivity to xenobiotic |
J:103181
|
increased pulmonary respiratory rate |
J:130701
|
increased pulmonary ventilation |
J:130701
|
increased systemic arterial diastolic blood pressure |
J:103181
|
increased systemic arterial systolic blood pressure |
J:103181
|
increased tidal volume |
J:130701
|
increased urine sodium level |
J:103181
|
polyuria |
J:103181
|
normal
taste/olfaction phenotype |
J:110704
|
Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2tm1Low/J
|
abnormal astrocyte physiology |
J:194407
|
abnormal GABAergic neuron morphology |
J:121219
|
abnormal neuronal migration |
J:121219
|
abnormal vocalization |
J:134260
|
astrocytosis |
J:194407
|
decreased body length |
J:106832
|
decreased body weight |
J:106832
|
decreased circulating growth hormone level |
J:106832
|
decreased circulating insulin-like growth factor I level |
J:106832
|
decreased inguinal fat pad weight |
J:106832
|
decreased liver weight |
J:106832
|
decreased physiological sensitivity to xenobiotic |
J:137069
|
decreased response to stress-induced hyperthermia |
J:137069
|
decreased spleen weight |
J:106832
|
decreased susceptibility to xenobiotic induced morbidity/mortality |
J:137069
|
increased circulating prolactin level |
J:106832
|
increased food intake |
J:106832
|
increased growth hormone level |
J:106832
|
increased interleukin-1 beta secretion |
J:194407
|
increased susceptibility to dopaminergic neuron neurotoxicity |
J:194407
|
microgliosis |
J:194407
|
normal
nervous system phenotype |
J:194407
|
postnatal growth retardation |
J:106832
|
short femur |
J:106832
|
Drd2tm1Low/Drd2tm1Low
either: B6.129S2-Drd2tm1Low or (involves: 129S2/SvPas * C57BL/6)
|
abnormal adenohypophysis morphology |
J:41858
|
abnormal pituitary gland morphology |
J:41858
|
adenohypophysis hyperplasia |
J:41858
|
adenohypophysis hypertrophy |
J:41858
|
adenohypophysis peliosis |
J:41858
|
decreased gonadotroph cell number |
J:41858
|
decreased physiological sensitivity to xenobiotic |
J:41858
|
enlarged pituitary gland |
J:41858
|
increased circulating prolactin level |
J:41858
|
increased lactotroph cell number |
J:41858
|
increased pituitary gland weight |
J:41858
|
short uterine horn |
J:41858
|
uterus adenomyosis |
J:41858
|
uterus cyst |
J:41858
|
uterus hyperplasia |
J:41858
|
Drd2tm1Low/Drd2tm1Low
involves: 129 * C57BL/6
|
abnormal locomotor activation |
J:102700
|
Drd2tm1Low/Drd2tm1Low
involves: 129S2/SvPas * C57BL/6J
|
abnormal locomotor activation |
J:47001
|
abnormal locomotor behavior |
J:47001
|
decreased physiological sensitivity to xenobiotic |
J:47001
|
decreased vertical activity |
J:47001
|
Drd2tm1Mok/Drd2tm1Mok
involves: 129S/SvEv
|
abnormal single cell response |
J:97412
|
Drd2tm1Mok/Drd2tm1Mok
involves: 129S/SvEv * C57BL/6J * DBA/2J
|
abnormal circulating hormone level |
J:97838
|
abnormal single cell response |
J:97838
|
darkened coat color |
J:97838
|
enlarged pituitary intermediate lobe |
J:97838
|
increased pituitary hormone level |
J:97838
|
Drd2tm1Schm/Drd2tm1Schm
B6.Cg-Drd2tm1Schm
|
abnormal intestinal absorption |
J:106280
|
abnormal intestinal transit time |
J:106280
|
abnormal large intestinal transit time |
J:106280
|
decreased body weight |
J:106280
|
increased defecation amount |
J:106280
|
increased fluid intake |
J:106280
|
increased food intake |
J:106280
|
Drd2tm1Schm/Drd2tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal dopamine level |
J:79483
|
abnormal locomotor behavior |
J:79483
|
bradykinesia |
J:79483
|
decreased body size |
J:79483
|
decreased body weight |
J:79483
|
hunched posture |
J:79483
|
premature death |
J:79483
|
Drd2tm1Smoc/Drd2tm1Smoc Tg(GFAP-cre)25Mes/0
involves: C57BL/6 * FVB/N
|
abnormal astrocyte physiology |
J:194407
|
astrocytosis |
J:194407
|
normal
nervous system phenotype |
J:194407
|
Drd2tm1Yyw/Drd2+
B6.129S4-Drd2tm1Yyw
|
abnormal behavioral response to xenobiotic |
J:82829
|
Drd2tm1Yyw/Drd2tm1Yyw
B6.129S4-Drd2tm1Yyw
|
abnormal behavioral response to xenobiotic |
J:65770,
J:82829
|
decreased anxiety-related response |
J:65770
|
decreased locomotor activity |
J:65770
|
decreased vertical activity |
J:65770
|
Drd2tm1Yyw/Drd2tm1Yyw
involves: 129S4/SvJae * C57BL/6
|
bradykinesia |
J:65770
|
decreased anxiety-related response |
J:65770
|
decreased locomotor activity |
J:65770
|
decreased vertical activity |
J:65770
|
impaired behavioral response to xenobiotic |
J:65770
|
Drd2tm1Yyw/Drd2tm1Yyw
involves: 129S4/SvJae * C57BL/6J
|
decreased aggression towards male mice |
J:103562
|
Drd2tm2Ebo/Drd2tm2Ebo
involves: 129S2/SvPas * C57BL/6
|
normal
behavior/neurological phenotype |
J:77277
|
enhanced behavioral response to xenobiotic |
J:77277
|
impaired behavioral response to xenobiotic |
J:77277
|
Drd2tm3.1Ebo/Drd2tm3.1Ebo En1tm2(cre)Wrst/En1+
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
|
abnormal dopamine level |
J:185643
|
abnormal nervous system electrophysiology |
J:185643
|
decreased physiological sensitivity to xenobiotic |
J:185643
|
enhanced behavioral response to anesthetic |
J:185643
|
enhanced behavioral response to cocaine |
J:185643
|
enhanced behavioral response to xenobiotic |
J:185643
|
hyperactivity |
J:185643
|
increased dopamine level |
J:185643
|
increased vertical activity |
J:185643
|
induced hyperactivity |
J:185643
|
Drd2tm3.1Ebo/Drd2tm3.1Ebo Tg(Drd1a-cre)AGsc/0
involves: 129S2/SvPas * C57BL/6 * FVB/N
|
abnormal dopamine level |
J:185643
|
abnormal nervous system electrophysiology |
J:185643
|
decreased locomotor activity |
J:185643
|
decreased physiological sensitivity to xenobiotic |
J:185643
|
impaired behavioral response to anesthetic |
J:185643
|
impaired behavioral response to cocaine |
J:185643
|
impaired coordination |
J:185643
|
normal
nervous system phenotype |
J:185643
|